{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:49:41Z","timestamp":1793828981699,"version":"4.6.1"},"reference-count":80,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1638,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1111\/j.1365-2036.2011.04619.x","type":"journal-article","created":{"date-parts":[[2011,3,9]],"date-time":"2011-03-09T02:16:31Z","timestamp":1299636991000},"page":"996-1009","source":"Crossref","is-referenced-by-count":65,"title":["Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis"],"prefix":"10.1111","volume":"33","author":[{"given":"M. S.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R.","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,8]]},"reference":[{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2036.2008.03751.x","article-title":"Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis - methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa","volume":"28","author":"Lichtenstein","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00365528209182073","article-title":"Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease","volume":"17","author":"Nielsen","year":"1982","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00063030-200115050-00005","article-title":"Tolerability of aminosalicylates in inflammatory bowel disease","volume":"15","author":"Ishaq","year":"2001","journal-title":"BioDrugs"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/gut.33.10.1338","article-title":"Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations","volume":"33","author":"DeVos","year":"1992","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1046\/j.1365-2036.1999.00642.x","article-title":"Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment","volume":"13","author":"Frieri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/BF01297074","article-title":"Very low intraluminal colonic pH in patients with active ulcerative colitis","volume":"38","author":"Fallingborg","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/187152807780077264","article-title":"Biological variability and targeted delivery of therapeutics for inflammatory bowel diseases: an in silico approach","volume":"6","author":"Haddish-Berhane","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1046\/j.1365-2036.1996.85257000.x","article-title":"5-aminosalicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine, or mesalazine","volume":"10","author":"Stretch","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2036.1990.tb00499.x","article-title":"Topical and systemic availability of 5-amino salicylate: comparisons of three controlled release preparations","volume":"4","author":"Christenson","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/0016-5085(87)90554-3","article-title":"Studies on the mechanism of bowel disturbance in ulcerative colitis","volume":"93","author":"Rao","year":"1987","journal-title":"Gastroenterology"},{"issue":"Suppl. 172","key":"10.1111\/j.1365-2036.2011.04619.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00365529009091905","article-title":"Gastrointestinal motility in patients with ulcerative colitis","volume":"25","author":"Rao","year":"1990","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2036.1995.tb00384.x","article-title":"Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis","volume":"9","author":"Marshall","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","article-title":"A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis","volume":"95","author":"Cohen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02236902","article-title":"Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis","volume":"41","author":"Gionchetti","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB16|cit16","first-page":"1338","article-title":"A comparison of mesalamine suspension enema and oral sulfasalzine for treatment of active distal ulcerative colitis in adults","volume":"91","author":"Kam","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB17|cit17","first-page":"1867","article-title":"A double blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.mib.0000231496.92013.85","article-title":"Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement","volume":"12","author":"Regueiro","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB21|cit21","article-title":"Excellent outcome of first attack of ulcerative colitis in three regional cohorts","volume":"116","author":"Farrokh-Yar","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/bmj.320.7242.1119","article-title":"Ulcerative colitis","volume":"320","author":"Ghosh","year":"2000","journal-title":"Br Med J"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB23|cit23","unstructured":"IMS Research. Prescription trends in 5-ASA use. Wellingborough, England, UK, 1992-2009"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3748\/wjg.v16.i21.2626","article-title":"Role of endoscopy in predicting disease course in inflammatory bowel disease","volume":"16","author":"Allez","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ibd.20997","article-title":"Importance of mucosal healing in ulcerative colitis","volume":"16","author":"Lichtenstein","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/BF01296108","article-title":"Better quality of life with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema","volume":"38","author":"Campieri","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00004836-198808000-00012","article-title":"5-aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?","volume":"10","author":"Campieri","year":"1988","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ibd.3780040202","article-title":"Dose-ranging study of mesalamine (Pentasa) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multi-centered placebo-controlled trial","volume":"4","author":"Hanauer","year":"1998","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB31|cit31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004115.pub2","article-title":"Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"1","author":"Marshall","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/j.1572-0241.2000.02180.x","article-title":"Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis","volume":"95","author":"Marshall","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","article-title":"5-aminosalicylic acid enemas in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis","volume":"92","author":"Sutherland","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/j.1572-0241.2005.00248.x","article-title":"Delayed-release oral mesalamine at 4.8\u2003g\/day (800\u2003mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial","volume":"100","author":"Hanauer","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1111\/j.1572-0241.2002.07103.x","article-title":"Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis","volume":"97","author":"Pruitt","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1365-2036.2006.03082.x","article-title":"Once daily MMX mesalazine for the treatment of mild to moderate ulcerative colitis: a phase II, dose-ranging study","volume":"24","author":"D\u2019Haens","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2006.10.025","article-title":"Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis","volume":"5","author":"Lichtenstein","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.MIB.0000171277.70404.40","article-title":"Efficacy and safety of mesalamine 1\u2003g HS versus 500\u2003mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study","volume":"11","author":"Lamet","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1365-2036.1997.00259.x","article-title":"Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis","volume":"11","author":"Gionchetti","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2036.1999.00482.x","article-title":"A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial","volume":"13","author":"Gionchetti","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB41|cit41","first-page":"677","article-title":"Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group","volume":"31","author":"Ardizzone","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"Suppl.","key":"10.1111\/j.1365-2036.2011.04619.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1007\/BF01312468","article-title":"Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories","volume":"32","author":"Williams","year":"1987","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1365-2036.1997.00193.x","article-title":"Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy","volume":"11","author":"Brown","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gut.40.6.775","article-title":"Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis","volume":"40","author":"Marshall","year":"1997","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB45|cit45","article-title":"Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis","volume":"100","author":"Lamers","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2036.1995.tb00421.x","article-title":"Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis","volume":"9","author":"Lemann","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.MIB.0000158386.25660.1e","article-title":"A new oral delivery system for 5-ASA: preliminary clinical findings for MMX","volume":"11","author":"Prantera","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/00365529609004876","article-title":"Changes in extent of ulcerative colitis: a study on the course and prognostic factors","volume":"31","author":"Langholz","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1572-0241.2000.t01-1-01770.x","article-title":"The natural history of ulcerative proctitis: a multicenter, retrospective study","volume":"95","author":"Meucci","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0016-5085(88)90569-0","article-title":"5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis","volume":"94","author":"Biddle","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB51|cit51","first-page":"1079","article-title":"5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a doubleblind placebo-controlled trial","volume":"85","author":"D\u2019Arienzo","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/gut.42.2.195","article-title":"Use of mesalazine slow release suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomised double-blind placebo controlled multicentre study","volume":"42","author":"Marteau","year":"1998","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1572-0241.1998.228_a.x","article-title":"Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial","volume":"93","author":"D\u2019Albasio","year":"1998","journal-title":"Am J Gastroentero"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB54|cit54","first-page":"121","article-title":"5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis","volume":"26","author":"Andreoli","year":"1994","journal-title":"Ital J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB55|cit55","first-page":"494","article-title":"Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis","volume":"44","author":"D\u2019Albasio","year":"1990","journal-title":"Dis Colon Rectum"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/BF02047216","article-title":"Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis","volume":"37","author":"Mantzaris","year":"1994","journal-title":"Dis Colon Rectum"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB57|cit57","first-page":"1143","article-title":"Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study","volume":"92","author":"D\u2019Albasio","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB58|cit58","article-title":"The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis","volume":"106","author":"Miner","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20041948","article-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma","volume":"201","author":"Rousseaux","year":"2005","journal-title":"J Exp Med"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0889-8553(05)70223-5","article-title":"Prostaglandin biology in inflammatory bowel disease","volume":"30","author":"Wallace","year":"2001","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/00365529109037024","article-title":"Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes","volume":"26","author":"Horn","year":"1991","journal-title":"Scand I Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1172\/JCI110474","article-title":"Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils","volume":"69","author":"Stenson","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/gut.32.1.50","article-title":"5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease","volume":"32","author":"Mahida","year":"1991","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/gut.33.7.929","article-title":"Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation","volume":"33","author":"Rachmilewitz","year":"1992","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF01300753","article-title":"Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid","volume":"36","author":"Fox","year":"1991","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0016-5085(99)70182-4","article-title":"Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes","volume":"116","author":"Kaiser","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB67|cit67","doi-asserted-by":"crossref","unstructured":"Egan LJ Mays DC Huntoon CJ et\u00a0al. Inhibition of interleukin-1-stimulated NF-kappaB RelA\/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity J Biol Chem 1999 274 26448 53","DOI":"10.1074\/jbc.274.37.26448"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/0016-5085(90)90329-Y","article-title":"Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid","volume":"98","author":"Ahnfelt-Ronne","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/gut.47.3.410","article-title":"Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis","volume":"47","author":"Frieri","year":"2000","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00054725-200108000-00007","article-title":"Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine","volume":"7","author":"Naganuma","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB71|cit71","first-page":"391","article-title":"Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis","volume":"7","author":"Kruis","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0016-5085(88)80061-1","article-title":"Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis","volume":"95","author":"Mulder","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/0003-4819-118-7-199304010-00009","article-title":"Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis","volume":"188","author":"Sutherland","year":"1993","journal-title":"Ann Int Med"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/gut.35.9.1282","article-title":"Optimum dose of olsalazine for maintaining remission in ulcerative colitis","volume":"35","author":"Travis","year":"1994","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2125.2000.00164.x","article-title":"Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters","volume":"49","author":"Hussain","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/gut.34.2.252","article-title":"Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor \u03b1: a novel mechanism of action of sulphasalazine","volume":"34","author":"Greenfield","year":"1993","journal-title":"Gut"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2011.04619.x-BIB77|cit77","article-title":"A prospective, blinded assessment of distal colonic mucosal concentrations of 5-ASA and NAC-5ASA in UC patients treated with either balsalazide (Colazal) or a pH-dependent mesalamine (Asacol)","volume":"130","author":"Kornbluth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/gut.31.11.1271","article-title":"Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion","volume":"31","author":"Staerk Laursen","year":"1990","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1007\/BF01540060","article-title":"Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis","volume":"34","author":"Vitti","year":"1989","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04619.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000235916","article-title":"Quality of life improvements attributed to combination therapy with oral and topical mesalamine in mild-to-moderately active ulcerative colitis","volume":"80","author":"Connolly","year":"2009","journal-title":"Digestion"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04619.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2011.04619.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T02:07:05Z","timestamp":1712282825000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04619.x"}},"subtitle":["Review: topical therapy in distal UC"],"short-title":[],"issued":{"date-parts":[[2011,3,8]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04619.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,8]]}}}